By Charles Bankhead
Source Medpagetoday
SAN ANTONIO — Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, a new analysis of a randomized trial showed.
Patients with a 21-gene assay score ≥31 had a 68% reduction in the risk of distant metastasis at 5 years when their chemotherapy included an anthracycline (such as doxorubicin). Distant relapse-free survival (DRFS) and overall survival (OS) also favored anthracycline-containing chemotherapy but did reach statistical significance. The magnitude of benefit increased with risk scores out to 50.
A subgroup analysis showed that the benefit in high-risk patients was limited to those with tumors >2 cm, reported Nan Chen, MD, of the University of Chicago, at the San Antonio Breast Cancer Symposiumopens in a new tab or window (SABCS).
“Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease,” she concluded.
Read more https://www.medpagetoday.com/meetingcoverage/sabcs/113395